Drug Profile
Rezpegaldesleukin - Nektar Therapeutics
Alternative Names: IL-2 conjugate; Interleukin-2 conjugate; LY-3471851; NKTR-358; PEG-conjugated rhIL-2; REZPEG - Nektar TherapeuticsLatest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Developer Eli Lilly and Company; Nektar Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Interleukins; Polyethylene glycols; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Interleukin-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia areata; Atopic dermatitis; Systemic lupus erythematosus
- Discontinued Psoriasis; Ulcerative colitis
Most Recent Events
- 04 Mar 2024 Phase-IIb clinical trials in Alopecia areata (SC) as of March 2024 (Nektar Therapeutics pipeline, March 2024)
- 23 Oct 2023 Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly) in USA (SC, Injection) (NCT06136741)
- 16 Oct 2023 Efficacy, adverse events and pharmacodynamics data from a phase Ib trial in Atopic dermatitis released by Nektar Therapeutics